Shire (SHP) Stock Price Up 0%
Shire PLC (LON:SHP) shares rose 0% during trading on Tuesday . The company traded as high as GBX 3,575 ($48.48) and last traded at GBX 3,549.09 ($48.13). Approximately 3,150,000 shares were traded during mid-day trading, an increase of 36% from the average daily volume of 2,310,000 shares. The stock had previously closed at GBX 3,549.09 ($48.13).
SHP has been the topic of a number of research analyst reports. Goldman Sachs Group reissued a “conviction-buy” rating on shares of Shire in a report on Tuesday, October 17th. Shore Capital reissued a “buy” rating on shares of Shire in a report on Monday, November 13th. Liberum Capital lowered their price target on Shire from GBX 4,400 ($59.67) to GBX 4,200 ($56.96) and set a “hold” rating on the stock in a report on Tuesday, October 24th. Morgan Stanley lowered their price target on Shire from GBX 5,800 ($78.65) to GBX 5,700 ($77.30) and set an “overweight” rating on the stock in a report on Thursday, October 12th. Finally, HSBC lowered their price target on Shire from GBX 4,050 ($54.92) to GBX 3,800 ($51.53) and set a “hold” rating on the stock in a report on Tuesday, November 21st. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Shire has a consensus rating of “Buy” and a consensus price target of GBX 5,082.35 ($68.92).
The company has a market cap of $31,840.00 and a PE ratio of 2,737.50.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.